A group of six leading Alzheimer’s experts has convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease.
The recommendations will help provide clinicians with greater clarity and more specific use of the new treatment, according to one of the experts, UNLV neuroscientist Dr. Jeffrey Cummings.
“Many details of the clinical use of this new agent are not in the FDA’s prescribing information,” said Cummings. “These recommendations fill the gap between the prescribing information and the real-world implementation of this treatment.”
The recommendations will be shared during a presentation at 10 a.m. EST on July 27 during the annual Alzheimer’s Association International Conference (AAIC). Cummings will co-chair the expert panel with Chief Science Officer, Maria C….
